BR112017015721A2 - expressão induzida de fator neurotrófico derivado do cérebro (bdnf) para o tratamento de doenças neuromusculares, neurodegenerativas, autoimunes, do desenvolvimento e/ou metabólicas. - Google Patents
expressão induzida de fator neurotrófico derivado do cérebro (bdnf) para o tratamento de doenças neuromusculares, neurodegenerativas, autoimunes, do desenvolvimento e/ou metabólicas.Info
- Publication number
- BR112017015721A2 BR112017015721A2 BR112017015721A BR112017015721A BR112017015721A2 BR 112017015721 A2 BR112017015721 A2 BR 112017015721A2 BR 112017015721 A BR112017015721 A BR 112017015721A BR 112017015721 A BR112017015721 A BR 112017015721A BR 112017015721 A2 BR112017015721 A2 BR 112017015721A2
- Authority
- BR
- Brazil
- Prior art keywords
- bdnf
- neuromuscular
- developmental
- neurodegenerative
- autoimmune
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A61K31/06—Phenols the aromatic ring being substituted by nitro groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562106365P | 2015-01-22 | 2015-01-22 | |
| PCT/US2016/014312 WO2016118741A1 (en) | 2015-01-22 | 2016-01-21 | Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017015721A2 true BR112017015721A2 (pt) | 2018-04-10 |
Family
ID=55310938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017015721A BR112017015721A2 (pt) | 2015-01-22 | 2016-01-21 | expressão induzida de fator neurotrófico derivado do cérebro (bdnf) para o tratamento de doenças neuromusculares, neurodegenerativas, autoimunes, do desenvolvimento e/ou metabólicas. |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US9763896B2 (enExample) |
| EP (2) | EP3247340B1 (enExample) |
| JP (3) | JP6951976B2 (enExample) |
| KR (1) | KR102690198B1 (enExample) |
| CN (2) | CN116617195A (enExample) |
| AU (2) | AU2016209255B2 (enExample) |
| BR (1) | BR112017015721A2 (enExample) |
| CA (1) | CA2974092A1 (enExample) |
| ES (1) | ES2961334T3 (enExample) |
| HK (1) | HK1247101A1 (enExample) |
| MX (2) | MX392410B (enExample) |
| PT (1) | PT3247340T (enExample) |
| WO (1) | WO2016118741A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116617195A (zh) * | 2015-01-22 | 2023-08-22 | 米托充制药公司 | 脑源性神经营养因子的诱导表达 |
| JP7090088B2 (ja) | 2017-01-06 | 2022-06-23 | リーヴス ファーマシューティカルズ、インコーポレイテッド | 新規フェニル誘導体 |
| US20180214395A1 (en) * | 2017-01-31 | 2018-08-02 | Paolo L. Manfredi | Compounds for Treatment or Prevention of Disorders of the Nervous System and Symptoms and Manifestations Thereof, and for Cyto-Protection Against Diseases and Aging of Cells, and Symptoms and Manifestations Thereof |
| US10660879B2 (en) | 2017-06-23 | 2020-05-26 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
| CA3061201A1 (en) | 2017-06-23 | 2018-12-27 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| JP2023544325A (ja) * | 2020-09-29 | 2023-10-23 | セフォ カンパニー リミテッド | Ｍａｎｆを含む神経精神疾患の予防または治療用組成物 |
| WO2023205625A2 (en) * | 2022-04-18 | 2023-10-26 | Mitochon Pharmaceuticals, Inc. | 2,4 dnp and prodrugs thereof for treatment of pulmonary and autoimmune diseases |
| WO2025051360A1 (en) * | 2023-09-06 | 2025-03-13 | Instituto de Medicina Molecular João Lobo Antunes | Trkb-t1 agonist for the treatment of absence seizure and/or comorbidities |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6664297B1 (en) * | 2000-10-18 | 2003-12-16 | Universidade Federal Do Rio De Janeiro | Methods for inhibition and dissolution of amyloidoses by administration of compositions comprising 2,4-dinitrophenol |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| EP1764095A1 (en) * | 2005-09-20 | 2007-03-21 | Revotar Biopharmaceuticals AG | Novel nitrocatechol derivatives having selectin ligand activity |
| US20100130597A1 (en) | 2007-07-06 | 2010-05-27 | The United State Of America, As Represented By The Secretary Of The Dept Of Health And Human Service | Dna-pkcs modulates energy regulation and brain function |
| JP6706204B2 (ja) * | 2013-08-30 | 2020-06-03 | イエール ユニバーシティ | 新規２，４−ジニトロフェノール製剤およびその使用法 |
| CN116617195A (zh) * | 2015-01-22 | 2023-08-22 | 米托充制药公司 | 脑源性神经营养因子的诱导表达 |
-
2016
- 2016-01-21 CN CN202211548767.9A patent/CN116617195A/zh active Pending
- 2016-01-21 KR KR1020177023034A patent/KR102690198B1/ko active Active
- 2016-01-21 CA CA2974092A patent/CA2974092A1/en active Pending
- 2016-01-21 JP JP2017539363A patent/JP6951976B2/ja active Active
- 2016-01-21 CN CN201680017379.4A patent/CN107405315A/zh active Pending
- 2016-01-21 EP EP16703409.9A patent/EP3247340B1/en active Active
- 2016-01-21 PT PT167034099T patent/PT3247340T/pt unknown
- 2016-01-21 BR BR112017015721A patent/BR112017015721A2/pt not_active Application Discontinuation
- 2016-01-21 US US15/002,531 patent/US9763896B2/en active Active
- 2016-01-21 WO PCT/US2016/014312 patent/WO2016118741A1/en not_active Ceased
- 2016-01-21 MX MX2017009402A patent/MX392410B/es unknown
- 2016-01-21 HK HK18106712.4A patent/HK1247101A1/zh unknown
- 2016-01-21 ES ES16703409T patent/ES2961334T3/es active Active
- 2016-01-21 EP EP23188878.5A patent/EP4306167B1/en active Active
- 2016-01-21 AU AU2016209255A patent/AU2016209255B2/en active Active
- 2016-11-21 US US15/357,412 patent/US9974755B2/en active Active
-
2017
- 2017-07-18 MX MX2022005937A patent/MX2022005937A/es unknown
- 2017-09-18 US US15/707,239 patent/US10220006B2/en active Active
-
2019
- 2019-01-17 US US16/250,470 patent/US10864173B2/en active Active
-
2020
- 2020-11-09 US US17/093,193 patent/US11717497B2/en active Active
-
2021
- 2021-03-01 JP JP2021031635A patent/JP7440092B2/ja active Active
- 2021-09-27 AU AU2021240120A patent/AU2021240120A1/en not_active Abandoned
-
2022
- 2022-10-03 JP JP2022159466A patent/JP2022173519A/ja active Pending
-
2023
- 2023-06-16 US US18/336,440 patent/US20240156750A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017015721A2 (pt) | expressão induzida de fator neurotrófico derivado do cérebro (bdnf) para o tratamento de doenças neuromusculares, neurodegenerativas, autoimunes, do desenvolvimento e/ou metabólicas. | |
| IL285151A (en) | Methods of treating fgf21-associated disorders | |
| DK4218640T3 (en) | Systems for the treatment of disease states and disorders | |
| HUE064141T2 (hu) | Azolopirimidin rákkal összefüggõ rendellenességek kezelésére | |
| IL258402A (en) | Electroporation for obesity or diabetes treatment | |
| HRP20210518T1 (hr) | Derivati 2,4-tiazolidindiona, namijenjeni liječenju poremećaja središnjeg živčanog sustava | |
| HUE054092T2 (hu) | Központi idegrendszeri zavarok kezelésére szolgáló kompozíciók és eljárások | |
| SG11201802145SA (en) | Novel lactobacillus and composition for preventing, improving, or treating degenerative brain diseases or cognitive function disorders | |
| GB201612165D0 (en) | Combinations for the treatment of type 2 diabetes | |
| IL269853A (en) | Proteins for the treatment of epithelial barrier activity disorders | |
| CL2018001502A1 (es) | Procedimiento para el tratamiento de efluente acuoso. | |
| EP3348273B8 (en) | Compositions based on xyloglucan and proteins for the treatment of intestinal disorders | |
| LT3377094T (lt) | Susilpninto virulentiškumo bakterijos, skirtos piktybinių solidinių navikų gydymui | |
| ZA202002993B (en) | Compounds for the treatment of neuromuscular disorders | |
| DK3624795T3 (da) | Kondenserede, heteroaromatiske anilinforbindelser til behandling af hudforstyrrelser | |
| GB201607388D0 (en) | Treatment of impulsivity-related disorders | |
| DK3723746T3 (da) | Phenoxysyrer til behandling af neuromuskulære lidelser | |
| DK3506956T3 (da) | Lægemiddel, særlig til behandling af fistler | |
| LT3448382T (lt) | Arimoklomolis, skirtas su gliukocerebrozidaze susijusiems sutrikimams gydyti | |
| HUE053358T2 (hu) | 5-Metil-6-fenil-4,5-dihidro-2H-piridazin-3-on származék agytumorok kezelésére | |
| SG11201703624PA (en) | Compounds for the diagnosis or treatment of disorders associated with protein or peptide oligomers | |
| LT3290436T (lt) | Fenilalanino neturintis baltymas, skirtas fenilketonurijos gydymui | |
| LT3364975T (lt) | Trazodono ir gabapentino derinys, skirtas skausmo gydymui | |
| LT3356337T (lt) | Tricikliniai dibenzotiazepino tipo junginiai, skirti cdkl5 sutrikimų gydyme | |
| LT3244889T (lt) | Farmacinė kompozicija, skirta mikozės gydymui |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |